ArticleAdvanced biomedical research2025
The Assessment of TECAR Therapy Efficacy to Manage Lateral Epicondylitis: A Randomized Clinical-Trial.
Article in Advanced biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lateral epicondylitis, a chronic painful condition within the lateral epicondyle, is one of the most prevalent arm pathologies. To date, various therapeutic strategies have been applied to manage the condition; however, they might be accompanied by adverse effects or temporary responses. TECAR therapy, a diathermy technique, has yielded promising outcomes in numerous musculoskeletal pathologies. The current study aims to investigate the impact of TECAR therapy on lateral epicondylitis. Materials and Methods: The current double-blinded randomized clinical trial has been conducted on 46 patients with lateral epicondylitis who were allocated into two groups of controls (treatment with 15 mg meloxicam and cock-up brace for the period of 2 weeks) and intervention who received similar treatment as well as five sessions of TECAR therapy (every other day in a week). Visual Analogue Scale (VAS) and Disabilities of the Arm, Shoulder and Hand (DASH) were applied to evaluate treatment response. Results: Both interventions led to significantly improved VAS ( Conclusion: Based on the findings of the current study, TECAR therapy is an effective modality for the treatment of lateral epicondylitis considering its remarkable influence on both pain relief and functional rehabilitation. Further studies are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.